India Glycols hosts analyst meet on September 10, 2026

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • India Glycols hosts non-deal analyst meet on September 10, 2026
  • Event will take place in person in Mumbai
  • Roadshow scheduled for September 11, 2026
  • Disclosures made under Regulation 30 of SEBI Listing Regulations
powered bylight_fuzz_icon
50351868

*this image is generated using AI for illustrative purposes only.

India Glycols Limited has scheduled a non-deal analyst and institutional investor meeting for Thursday, September 10, 2026. The event will be held in person in Mumbai.

The company disclosed the schedule pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Discussions during the interaction will be based solely on publicly available information. No unpublished price-sensitive information is intended to be shared.

Meeting Schedule

The firm will also conduct a roadshow on Friday, September 11, 2026. The company noted that changes to the schedule may occur due to exigencies involving participants or the host.

Date Event Mode Location
September 10, 2026 Non-Deal Meeting In-Person Mumbai
September 11, 2026 Roadshow N/A N/A

Ankur Jain, Head (Legal) & Company Secretary, signed the disclosure letter dated September 7, 2026. The intimation is hosted on the company's website for record purposes.

Historical Stock Returns for India Glycols

1 Day5 Days1 Month6 Months1 Year5 Years
+4.99%-76.80%-76.51%-68.05%-67.80%0.0%

How might India Glycols' upcoming strategic disclosures influence its valuation multiples relative to the broader chemical sector?

What specific operational or financial metrics are analysts likely to scrutinize during the September 10 non-deal meeting?

Could the scheduled roadshow signal preparations for a future capital raise, merger, or acquisition activity?

Three Ennature Bio Pharma directors resign amid India Glycols merger

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Three non-executive directors of Ennature Bio Pharma resigned effective September 7, 2026
  • Manish Chandra Pant, Bhupendar Pal Singhal, and Shashi Kant Shukla cited personal reasons
  • Disclosure made by India Glycols as part of ongoing Scheme of Arrangement compliance
  • Update responds to observation letters from NSE and BSE regarding the merger process
powered bylight_fuzz_icon
50338132

*this image is generated using AI for illustrative purposes only.

India Glycols Limited disclosed on September 7, 2026, that three non-executive directors of Ennature Bio Pharma Limited (EBL) have resigned with immediate effect. The development relates to the ongoing Scheme of Arrangement between the two companies.

The resignations were communicated by EBL to India Glycols in a letter dated September 7, 2026. This disclosure addresses observation letters issued earlier this year by the National Stock Exchange of India Limited and BSE Limited regarding the merger process.

Director Resignations

Three non-executive directors stepped down from EBL’s board due to personal reasons. The resignations took effect immediately upon submission.

Director Name DIN Reason for Change
Manish Chandra Pant 08850173 Personal reasons
Bhupendar Pal Singhal 08850152 Personal reasons
Shashi Kant Shukla 07117368 Personal reasons

Akshay Bansal, Executive Director of EBL, confirmed the exits in correspondence with India Glycols. The filing references SEBI Master Circular No. HO/4911 411 4(7)2025-CFD-POD211 13762/2026 dated January 30, 2026, as the regulatory basis for this update.

Scheme Context

The resignation update is part of the compliance requirements for the Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013. The scheme involves India Glycols Limited, IGL Spirits Limited, and their respective shareholders alongside EBL.

The stock exchanges had previously issued observation letters on November 17, 2025, and November 19, 2025, seeking clarification on material events related to the proposed arrangement.

Historical Stock Returns for India Glycols

1 Day5 Days1 Month6 Months1 Year5 Years
+4.99%-76.80%-76.51%-68.05%-67.80%0.0%

How might the departure of these three non-executive directors impact the regulatory approval timeline for the Scheme of Arrangement between India Glycols and Ennature Bio Pharma?

Will the resignations trigger any additional compliance requirements or scrutiny from SEBI regarding the governance structure of EBL during the merger process?

Are there plans to appoint new non-executive directors to replace the resigned members, and how might their profiles influence the strategic direction of the combined entity?

More News on India Glycols

1 Year Returns:-67.80%